Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
B-cell Malignancies
DRUG: Zanubrutinib|DRUG: Tislelizumab
Incidence of Adverse Events (AEs), Safety as assessed by incidence of all treatment-emergent adverse events (TEAEs) and serious AEs (SAEs), Up to 5 years
Progression-Free Survival (PFS) per investigator assessment, Time from the starting date of zanubrutinib in the eligible BeiGene study to the date of first documentation of disease progression or death, whichever occurs first, Up to 5 years|Duration of Response (DOR) per investigator assessment, Time from the date that response criteria are first met after the start of zanubrutinib in the eligible BeiGene study to the date that progressive disease (PD) is objectively documented or death, whichever occurs first, Up to 5 years|Overall Survival (OS), Time from the starting date of zanubrutinib in the eligible BeiGene study to the date of death due to any reason, Up to 5 years
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.